NEW YORK (GenomeWeb News) – Proteomic diagnostics company Power3 Medical Products is collaborating with the Princess Haya Biotechnology Center at the Jordan University of Science and Technology for a clinical validation study of the company’s BC-SeraPro Breast Cancer diagnostic blood test.
Under the program, the Princess Haya center and Jordan University will provide breast cancer, benign breast disease, and age-matched control patient samples that the company will analyze using its panel of protein biomarkers.
Power3 said it plans to finish the clinical validation study in the third quarter of this year and to launch the BC-SeraPro in the first quarter of 2009. The company said it aims to develop a protein biomarker-based diagnostic test that can be applied “regardless of a woman’s genetic makeup or ethnicity.”
Among women in Jordan, breast cancer is the leading form of cancer and the second leading cause of death.
Power3 also is involved in clinical evaluation studies for its NuroPro blood-based test for Parkinson’s disease with the University of Thessaly Medical School in Greece and at the Cleo Roberts Center for Clinical Research at the Sun Health Research Institute in Sun City, Arizona.
The company also said it expects to introduce the NuroPro diagnostic for Parkinson’s and Alzheimer’s diseases in international markets later this year and in the US soon afterward.